Cargando…

Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors

There have been unique adverse events reported with targeted blockade of programmed death-1 (PD-1), programmed death-ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA4), including immune mediated toxicities. Recently, there have been reports of hepatitis B reactivation (HBVr) o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burns, Ethan A., Muhsen, Ibrahim N., Anand, Kartik, Xu, Jiaqiong, Umoru, Godsfavour, Arain, Abeer N., Abdelrahim, Maen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Clinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946380/ https://www.ncbi.nlm.nih.gov/pubmed/33480637 http://dx.doi.org/10.1097/CJI.0000000000000358

Ejemplares similares

Acquired haemophilia as a paraneoplastic manifestation of pancreatic cancer
por: Arain, Abeer, et al.
Publicado: (2020)

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
por: Haque, Emaan, et al.
Publicado: (2022)

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer
por: Burns, Ethan A., et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
por: Abboud, Karen, et al.
Publicado: (2023)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
por: Badheeb, Mohamed, et al.
Publicado: (2022)

Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease
por: Allen, Emily, et al.
Publicado: (2023)

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
por: Lin, Jamie S, et al.
Publicado: (2020)

Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System
por: Mina, Syeda A., et al.
Publicado: (2021)

Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
por: Haque, Emaan, et al.
Publicado: (2022)

Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
por: Kawashima, Shun, et al.
Publicado: (2022)

Pancreatic head vs pancreatic body/tail cancer: Are they different?
por: Sun, Kai, et al.
Publicado: (2022)

Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab
por: Qureshi, Sehrish, et al.
Publicado: (2023)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

Checkpoint inhibitor-related renal vasculitis and use of rituximab
por: Mamlouk, Omar, et al.
Publicado: (2020)

Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review
por: Reddy, Tejaswini Parlapalle, et al.
Publicado: (2020)

Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data
por: Umoru, Godsfavour, et al.
Publicado: (2020)

Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
por: Abdelrahim, Maen, et al.
Publicado: (2021)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Infliximab for the treatment of patients with checkpoint inhibitor–associated acute tubular interstitial nephritis
por: Lin, Jamie S., et al.
Publicado: (2021)

T-cell lymphoma secondary to checkpoint inhibitor therapy
por: Anand, Kartik, et al.
Publicado: (2020)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Primary cardiac angiosarcoma diagnosed in the first trimester of pregnancy
por: Burns, Ethan A, et al.
Publicado: (2019)

Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor
por: Chang, Lele, et al.
Publicado: (2022)

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
por: Mamlouk, Omar, et al.
Publicado: (2019)

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors
por: Wang, Mu-Qi, et al.
Publicado: (2022)

Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy
por: Rubin, Samuel J S, et al.
Publicado: (2022)

Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
por: Elsayed, Marwa, et al.
Publicado: (2021)

Are we over-treating with checkpoint inhibitors?
por: Danson, Sarah, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
por: Chitturi, Kalyan R., et al.
Publicado: (2019)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
por: Yu, Kenneth H., et al.
Publicado: (2021)

Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review
por: Zhao, Jian, et al.
Publicado: (2022)

Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
por: Xia, Zhengzheng, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Immune Checkpoint Inhibitor Exposure in Pregnancy: A Scoping Review
por: Salehi, Iman, et al.
Publicado: (2022)

Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data
por: Nie, Run-Cong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8q3irmmhdgf20u952lebd1l730